Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients as an add-on therapy to levodopa/carbidopa. While we had expected approval (following the revised PDUFA date of 21 March), the certainty of approval removes a major overhang on the stock, and as such we expect a positive share price reaction. We expect launch in the US market in H217 by sub licensee US WorldMeds. Our valuation of Newron remai
22 Mar 2017
Xadago receives FDA approval in PD
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Xadago receives FDA approval in PD
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
22 Mar 2017 -
Author:
Dr Susie Jana -
Pages:
2
Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients as an add-on therapy to levodopa/carbidopa. While we had expected approval (following the revised PDUFA date of 21 March), the certainty of approval removes a major overhang on the stock, and as such we expect a positive share price reaction. We expect launch in the US market in H217 by sub licensee US WorldMeds. Our valuation of Newron remai